[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera

P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer… - Cell, 2021 - cell.com
P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, HME Duyvesteyn
Cell, 2021cell.com
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the
pandemic and error-prone virus replication is leading to the appearance of mutant viruses
and potentially escape from antibody responses. Variant B. 1.1. 7, now dominant in the UK,
with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in
the ACE2 interacting surface. We examine the ability of B. 1.1. 7 to evade antibody …
Summary
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.
cell.com